# Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

> **NCT01339091** · PHASE3 · COMPLETED · sponsor: **Durata Therapeutics Inc., an affiliate of Allergan plc** · enrollment: 573 (actual)

## Conditions studied

- Abscess
- Wound Infection
- Surgical Site Infection
- Cellulitis

## Interventions

- **DRUG:** Dalbavancin
- **DRUG:** Vancomycin / Linezolid

## Key facts

- **NCT ID:** NCT01339091
- **Lead sponsor:** Durata Therapeutics Inc., an affiliate of Allergan plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2012-09
- **Final completion:** 2012-11
- **Target enrollment:** 573 (ACTUAL)
- **Last updated:** 2014-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01339091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01339091, "Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01339091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*